- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04033211
NOVOsyn® for Trocar Incision After Laparoscopic Appendectomy and Cholecystectomy (NOVOTILAC)
Randomized, Multi-center, Double Blinded, Prospective Study to Evaluate the Incidence of Complications in Laparoscopic Cholecystectomy and Appendectomy Using Novosyn® CHD Versus Novosyn® Suture Material to Close Trocar Wound
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The bacteriostatic and bactericidal effect of Novosyn® CHD will be assessed by the incidence of surgical site infection (SSI) in each suture group until 30 days postoperatively. The frequency of infections (SSI: A1 and A2) is considered as a suitable parameter for the assessment of efficacy. It is expected that the use of the Novosyn® CHD suture will reduce the occurrence of infections (SSI: A1 and A2) 30 days postoperatively compared to Novosyn suture (primary objective). SSI will be classified according to the Centre of Disease Control and Prevention (CDC), therefore the time point for assessment of SSI as set to 30 days postoperatively.
Furthermore, short-term and long-term complications, the handling of the suture material, length of postoperative hospital stay, costs, pain, quality of life, time to return to work, hernia rate including umbilical hernias and the cosmetic outcome will also be assessed as secondary objectives.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Leonberg, Baden-Württemberg, Germany, 71229
- Klinikverbund Südwest Krankenhaus Leonberg Alllgemeinchirurgie
-
Schwäbisch Hall, Baden-Württemberg, Germany, 74523
- Diakonie Klinikum gGmbH Schwäbisch Hall
-
-
-
-
-
Badalona, Spain, 08916
- Hospital Germans Trias i Pujol General and Digestive Surgery
-
Barcelona, Spain, 08006
- General Surgery Department Hospital Plató
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or cholecystectomy.
- Written informed consent
- Age≥ 18 years
- Not incapacitated patient
Exclusion Criteria:
- Open surgery for appendectomy or cholecystectomy
- Pregnancy
- Allergy or hypersensitivity to chlorhexidine
- Intraoperatively conversion from laparoscopic to open surgery
- Patients taking medical consumption that might affect wound healing
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Novosyn® CHD
A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using Novosyn® CHD suture for fascia and skin closure of trocar wounds.
|
Experimental
|
Novosyn®
A population undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or a primary emergency or early elective laparoscopic cholecystectomy using either Novosyn® suture for fascia and skin closure of trocar wounds.
|
Comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical Site Infection
Time Frame: until 30 days + 10 days after surgery
|
Incidence of postoperative surgical site infections, SSI (A1: Superficial incisional site infections and A2: Deep incisional surgical site infections) (efficacy parameter) Surgical Site Infection (SSI) is defined according to the definition of the US Centres for Disease Control and Prevention (CDC).
|
until 30 days + 10 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of Wound Dehiscence
Time Frame: until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
|
Incidence of wound dehiscence (skin) at different postoperative examinations
|
until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
|
Reoperation Rate
Time Frame: until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
|
Incidence of reoperation rate at different postoperative times
|
until discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
|
Mortality Rate
Time Frame: until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively
|
Incidence of mortality rate at different postoperative times
|
until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively
|
Postoperative Complications during the postoperative Course
Time Frame: until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively
|
Rates of postoperative complications such as bleeding, tissue reaction, abscess, perforation, bile leaks, biliary peritonitis, ileus, stenosis, fistula at different postoperative points in time
|
until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively
|
Suture Removal due to Wound Problems during the postoperative Course
Time Frame: until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively
|
Rate of suture removal due to wound problems (infection, dehiscence, residual material requiring removal) at different defined postoperative points in time
|
until discharge (ca. 10 days postop), 30 days +10 days, and 1 year ±2 months postoperatively
|
Length of hospital stay
Time Frame: until discharge (ca. 10 days postop)
|
Defined as the time period from day of operation until day of discharge (efficacy parameter).
|
until discharge (ca. 10 days postop)
|
Postoperative Surgical Site Infections
Time Frame: 1 year ±2 months post-op
|
Incidence of postoperative surgical site infections
|
1 year ±2 months post-op
|
Rate of Conversion to open surgery
Time Frame: intraoperatively
|
Number of interventions where operation technique has to be converted to open surgery intraoperatively
|
intraoperatively
|
Time to return to work
Time Frame: up to 1 year ±2 months
|
Defined as the duration (days) from day of surgery until the day when the patient was able to work.
Employment status of the patient will also be reported.
|
up to 1 year ±2 months
|
Course of Pain: Visual Analogue Scale (VAS)
Time Frame: preoperatively, at day of discharge (ca. 10 days postop), at 30 days +10 days and 1 year ±2 months postoperatively
|
This parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "maximal pain".
The values are compared over postoperative period.
|
preoperatively, at day of discharge (ca. 10 days postop), at 30 days +10 days and 1 year ±2 months postoperatively
|
Course of Cosmetic result
Time Frame: 30 days +10 days, 1 year ±2 months postoperatively
|
Overall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS).
Cosmetic result and the scar will be evaluated by the patient and the physician.
Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each.
The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each.
The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum)
|
30 days +10 days, 1 year ±2 months postoperatively
|
Course of Overall patient and observer satisfaction with the scar: Patient and Observer Scar Assessment Scale (POSAS)
Time Frame: 30 days +10 day, 1 year ±2 months postoperatively
|
Overall patient and observer satisfaction with the scar using the Patient and Observer Scar Assessment Scale (POSAS).
Cosmetic result and the scar will be evaluated by the patient and the physician.
Patient will rate the cosmetic outcome in six categories (Pain, Itching, Color of scar, Stiffness of scar, thickness and irregularity of scar) on a 1 to 10 points scale each.
The physician will use the Observer component, rating vascularization, pigmentation, thickness, relief and pliability of the scar on a 1 to 10 points scale each.
The categories are added to a total POSAS score of 11 (minimum) to 110 points (maximum)
|
30 days +10 day, 1 year ±2 months postoperatively
|
Comparison of wound appearance
Time Frame: discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
|
Photographic documentation of the wounds for assessment
|
discharge (ca. 10 days postop), 30 days +10 days and 1 year ±2 months postoperatively
|
Comparison of handling parameters of the suture materials
Time Frame: intraoperatively
|
Comparison of the handling features of the suture materials in eight different categories (ease of passage of the suture, first throw knot holding, knot tie down smoothness, knot security, surgical hand, memory effect, lack of frying and the overall handling) by rating each category on a 5 point scale (excellent, very good, good, satisfied, poor); no overall score is calculated, the categories are compared separately
|
intraoperatively
|
Course of Health Status
Time Frame: 30 days +10 days after surgery, 1 year ±2 months after surgery
|
EQ-5D is a standardised measure of health status developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal.
EQ-5D is designed for self-completion by respondents and it takes only a few minutes to complete.
Instructions to respondents are included in the questionnaire.
EQ-5D-5L consists of 2 pages - descriptive system and the EQ visual Analogue scale (EQ-VAS).
The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression).
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
The EQ VAS records the respondents self rated health on a 20 cm vertical , visual analogue scale with endpoints labelled "the best health you can imagine" and " the worst health you can imagine"
|
30 days +10 days after surgery, 1 year ±2 months after surgery
|
Hernia Rate / Umbilical Hernia Rate
Time Frame: until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively
|
Hernia rate including umbilical hernia postoperatively verified by ultra-sound examination compared at different postoperative points in time
|
until discharge (ca. 10 days postop), 30 days +10 days, 1 year ±2 months postoperatively
|
Costs (economics)
Time Frame: 1 year ±2 months
|
Assessment of costs will be calculated on postoperative complication (SSI) in both suture groups (efficient parameter).
|
1 year ±2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Markus Golling, Prof. Dr., Diakonie Klinikum gGmbH Schwäbisch Hall
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAG-O-H-1816
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholecystitis
-
The University of Texas Health Science Center at...CompletedAcute Cholecystitis | Chronic CholecystitisUnited States
-
Azienda Ospedaliero, Universitaria PisanaCompletedAcute CholecystitisItaly
-
University Hospital, GhentCompletedUncomplicated Acute CholecystitisBelgium, Qatar
-
Ain Shams UniversityCompletedCholecystitis | Chronic Calculous Cholecystitis | Acute Calculous CholecystitisEgypt
-
Konya Meram State HospitalCompleted
-
Pirogov Russian National Research Medical UniversityCompletedAcute Cholecystitis | Gangrenous CholecystitisRussian Federation
-
Hospital del MarCompletedAcute Cholecystitis
-
South Valley UniversityCompletedAcute CholecystitisEgypt
-
Asklepios Klinik LangenUniversity Hospital FrankfurtCompletedAcute Cholecystitis
-
University of CataniaCompleted
Clinical Trials on Novosyn® CHD for fascia and skin closure
-
Ulthera, IncCompletedHyperhidrosisUnited States
-
Ulthera, IncCompleted
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, France; W.L.Gore & Associates; Abbott; Centre Hospitalier St... and other collaboratorsNot yet recruitingPatent Foramen Ovale | Cryptogenic Ischemic StrokeFrance
-
Assistance Publique - Hôpitaux de ParisCompletedIschemic Stroke | Migraine | Patent Foramen Ovale | Atrial Septal AneurysmFrance
-
Ulthera, IncCompleted
-
Universidad de ExtremaduraCompletedPain | Foot Diseases | MetatarsalgiaSpain